Type 2 diabetes
The management of type 2 diabetes

This is an update of
NICE clinical guidelines E, F, G and H
NICE clinical guideline 66
Type 2 diabetes: the management of type 2 diabetes

Ordering information
You can download the following documents from www.nice.org.uk/CG066
- The NICE guideline (this document) – all the recommendations.
- A quick reference guide – a summary of the recommendations for healthcare professionals.
- ‘Understanding NICE guidance’ – information for patients and carers.
- The full guideline – all the recommendations, details of how they were developed, and reviews of the evidence they were based on.

For printed copies of the quick reference guide or ‘Understanding NICE guidance’, phone NICE publications on 0845 003 7783 or email publications@nice.org.uk and quote:
- N1572 (quick reference guide)
- N1573 (‘Understanding NICE guidance’).

NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales

This guidance represents the view of the Institute, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer and informed by the summary of product characteristics of any drugs they are considering.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

National Institute for Health and Clinical Excellence

MidCity Place
71 High Holborn
London WC1V 6NA

www.nice.org.uk

© National Institute for Health and Clinical Excellence, 2008. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of the Institute.
## Contents

Introduction ......................................................................................................5  
Patient-centred care ..........................................................................................6  
Key priorities for implementation ....................................................................7  
1 Guidance .....................................................................................................8  
  1.1 Patient education ..................................................................................8  
  1.2 Lifestyle management/non-pharmacological management .................9  
  1.3 Glucose control levels .........................................................................11  
  1.4 Self-monitoring of plasma glucose .....................................................12  
  1.5 Oral glucose control therapies (1): metformin, insulin secretagogues and acarbose .................................................................13  
  1.6 Oral glucose control therapies (2): other oral agents and exenatide 15  
  1.7 Glucose control: insulin therapy .......................................................17  
  1.8 Blood pressure therapy ......................................................................20  
  1.9 Cardiovascular risk estimation ............................................................22  
  1.10 Management of blood lipid levels ...................................................22  
  1.11 Anti-thrombotic therapy ...................................................................25  
  1.12 Kidney damage ................................................................................26  
  1.13 Eye damage ......................................................................................27  
  1.14 Nerve damage ..................................................................................29  
2 Notes on the scope of the guidance ............................................................31  
3 Implementation ............................................................................................32  
4 Research recommendations ..........................................................................33  
5 Other versions of this guideline ..................................................................35  
6 Related NICE guidance ...............................................................................35  
7 Updating the guideline ................................................................................37  
Appendix A: The Guideline Development Group ...........................................38  
Appendix B: The Guideline Review Panel .....................................................41  
Appendix C: The algorithms ..........................................................................42
This clinical guideline is an update of, and will replace, these NICE clinical guidelines:


The guideline will update and replace the recommendations on type 2 diabetes in these NICE technology appraisals:


The Guideline Development Group considered including sitagliptin and insulin detemir in this guideline; however, it was advised by NICE not to do so. NICE is undertaking a rapid update of recommendations in this guideline on second- and third-line drugs for managing blood glucose, which will cover these drugs. The updated guideline will be published early in 2009. For more information, see www.nice.org.uk and search for ‘type 2 diabetes newer agents’.
Introduction

Type 2 diabetes is commonly associated with raised blood pressure, a disturbance of blood lipid levels and a tendency to develop thrombosis. It is notable for the increased cardiovascular risk that it carries: coronary artery disease (leading to heart attacks, angina); peripheral artery disease (leg claudication, gangrene); and carotid artery disease (strokes, dementia). The specific ('microvascular') complications of diabetes include eye damage (blindness), kidney damage (sometimes requiring dialysis or transplantation) and nerve damage (resulting in amputation, painful symptoms, erectile dysfunction, other problems). This picture of multiple vascular risk factors and wide-ranging complications means that the management of type 2 diabetes draws on many areas of healthcare management. As a result, diabetes care is typically complex and time-consuming. The necessary lifestyle changes, the complexities of management and the side effects of therapy make self-monitoring and education for people with diabetes central parts of management.

Definition

The guideline recommendations were developed using the World Health Organization (WHO) definition of diabetes, which requires a degree of high plasma glucose levels sufficient to put the individual at risk of the microvascular complications of diabetes. This definition was re-confirmed by WHO in 2006 but, like earlier versions, it does not contain a specific definition for type 2 diabetes. A person is normally thought to have type 2 diabetes if he or she does not have type 1 diabetes (rapid onset, often in childhood, insulin-dependent, ketoacidosis if neglected), monogenetic diabetes or other medical conditions or treatment suggestive of secondary diabetes. Diagnosis is not addressed in this guideline.

Patient-centred care

This guideline offers best practice advice on the care of people with type 2 diabetes. It does not address care in or before pregnancy, or care by specialist services for specific advanced organ damage (cardiac, renal, eye, vascular, stroke and other services).

Management of diabetes typically involves a considerable element of self-care, and advice should, therefore, be aligned with the perceived needs and preferences of people with diabetes, and carers. People with type 2 diabetes should have the opportunity to make informed decisions about their care and treatment, in partnership with their healthcare professionals. If patients do not have the capacity to make decisions, healthcare professionals should follow the Department of Health guidelines – ‘Reference guide to consent for examination or treatment’ (2001) (available from www.dh.gov.uk). Healthcare professionals should also follow a code of practice accompanying the Mental Capacity Act (summary available from www.publicguardian.gov.uk).

Good communication between healthcare professionals and patients is essential. It should be supported by evidence-based written information tailored to the patient’s needs. Treatment and care, and the information patients are given about it, should be culturally appropriate. It should also be accessible to people with additional needs such as physical, sensory or learning disabilities, and to people who do not speak or read English.

If the patient agrees, families and carers should have the opportunity to be involved in decisions about treatment and care.

Families and carers should also be given the information and support they need.
Key priorities for implementation

- Offer structured education to every person and/or their carer at and around the time of diagnosis, with annual reinforcement and review. Inform people and their carers that structured education is an integral part of diabetes care.
- Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.
- When setting a target glycated haemoglobin ($\text{HbA}_{1c}$):
  - involve the person in decisions about their individual $\text{HbA}_{1c}$ target level, which may be above that of 6.5% set for people with type 2 diabetes in general
  - encourage the person to maintain their individual target unless the resulting side effects (including hypoglycaemia) or their efforts to achieve this impair their quality of life
  - offer therapy (lifestyle and medication) to help achieve and maintain the $\text{HbA}_{1c}$ target level
  - inform a person with a higher $\text{HbA}_{1c}$ that any reduction in $\text{HbA}_{1c}$ towards the agreed target is advantageous to future health
  - avoid pursuing highly intensive management to levels of less than 6.5%.
- Offer self-monitoring of plasma glucose to a person newly diagnosed with type 2 diabetes only as an integral part of his or her self-management education Discuss its purpose and agree how it should be interpreted and acted upon.
- When starting insulin therapy, use a structured programme employing active insulin dose titration that encompasses:
  - structured education
  - continuing telephone support
  - frequent self-monitoring
  - dose titration to target
  - dietary understanding
  - management of hypoglycaemia
  - management of acute changes in plasma glucose control
  - support from an appropriately trained and experienced healthcare professional.
1 Guidance

The following guidance is based on the best available evidence. The full guideline (www.rcplondon.ac.uk/pubs/brochure.aspx?e=247) gives details of the methods and the evidence used to develop the guidance.

1.1 Patient education

1.1.1 Offer structured education to every person and/or their carer at and around the time of diagnosis, with annual reinforcement and review. Inform people and their carers that structured education is an integral part of diabetes care.

1.1.2 Select a patient-education programme that meets the criteria laid down by the Department of Health and Diabetes UK Patient Education Working Group.

- Any programme should be evidence-based and suit the needs of the individual. The programme should have specific aims and learning objectives, and should support development of self-management attitudes, beliefs, knowledge and skills for the learner, their family and carers.
- The programme should have a structured curriculum that is theory driven and evidence-based, resource-effective, has supporting materials, and is written down.
- The programme should be delivered by trained educators who have an understanding of education theory appropriate to the age and needs of the programme learners, and are trained and competent in delivery of the principles and content of the programme they are offering.

2 The recommendations in this section replace ‘Guidance on the use of patient-education models for diabetes’ (NICE technology appraisal guidance 60).

• The programme itself should be quality assured, and be reviewed by trained, competent, independent assessors who assess it against key criteria to ensure sustained consistency.
• The outcomes from the programme should be regularly audited.

1.1.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.

1.1.4 Offer group education programmes as the preferred option. Provide an alternative of equal standard for a person unable or unwilling to participate in group education.

1.1.5 Ensure the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs in the locality.

1.1.6 Ensure all members of the diabetes healthcare team are familiar with the programmes of patient education available locally, that these programmes are integrated with the rest of the care pathway, and that people with diabetes and their carers have the opportunity to contribute to the design and provision of local programmes.

1.2 Lifestyle management/non-pharmacological management

Neither the management of obesity nor smoking cessation is specifically addressed in this guideline. Follow other NICE guidance in these areas (see section 6 for further details).

1.2.1 Dietary advice

1.2.1.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.

1.2.1.2 Provide dietary advice in a form sensitive to the individual's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.
Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to people with type 2 diabetes. Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.

Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.

Target, for people who are overweight, an initial body weight loss of 5–10%, while remembering that lesser degrees of weight loss may still be of benefit and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.

Individualise recommendations for carbohydrate and alcohol intake, and meal patterns. Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.

Advise individuals that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that care should be taken to avoid excess energy intake.

Discourage the use of foods marketed specifically for people with diabetes.

When patients are admitted to hospital as inpatients or to any other institutions, implement a meal-planning system that provides consistency in the carbohydrate content of meals and snacks.

**Management of depression**

Follow the recommendations in ‘Depression: management of depression in primary and secondary care clinical guideline’ (NICE clinical guideline 23).
1.3  **Glucose control levels**

1.3.1 When setting a target glycated haemoglobin (HbA\(_1c\)):

- involve the person in decisions about their individual HbA\(_1c\) target level, which may be above that of 6.5% set for people with type 2 diabetes in general
- encourage the person to maintain their individual target unless the resulting side effects (including hypoglycaemia) or their efforts to achieve this impair their quality of life
- offer therapy (lifestyle and medication) to help achieve and maintain the HbA\(_1c\) target level
- inform a person with a higher HbA\(_1c\) that any reduction in HbA\(_1c\) towards the agreed target is advantageous to future health
- avoid pursuing highly intensive management to levels of less than 6.5%.

1.3.2 Measure the individual’s HbA\(_1c\) levels at:

- 2–6-monthly intervals (tailored to individual needs) until the blood glucose level is stable on unchanging therapy; use a measurement made at an interval of less than 3 months as an indicator of direction of change, rather than as a new steady state
- 6-monthly intervals once the blood glucose level and blood glucose-lowering therapy are stable.

1.3.3 If HbA\(_1c\) levels remain above target levels, but pre-meal self-monitoring levels remain well controlled (< 7.0 mmol/litre), consider self-monitoring to detect postprandial hyperglycaemia (> 8.5 mmol/litre) and manage to below this level if detected (see sections 1.5–1.7).

1.3.4 Measure HbA\(_1c\) using high-precision methods and report results in units aligned with those used in the DCCT trial\(^4\) (or as

---

recommended by national agreement after publication of this guideline).

1.3.5 When HbA\textsubscript{1c} monitoring is invalid (because of disturbed erythrocyte turnover or abnormal haemoglobin type), estimate trends in blood glucose control using one of the following:
- fructosamine estimation
- quality-controlled plasma glucose profiles
- total glycated haemoglobin estimation (if abnormal haemoglobins).

1.3.6 Investigate unexplained discrepancies between HbA\textsubscript{1c} and other glucose measurements. Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.

1.4 **Self-monitoring of plasma glucose**

1.4.1 Offer self-monitoring of plasma glucose to a person newly diagnosed with type 2 diabetes only as an integral part of his or her self-management education. Discuss its purpose and agree how it should be interpreted and acted upon.

1.4.2 Self-monitoring of plasma glucose should be available:
- to those on insulin treatment
- to those on oral glucose-lowering medications to provide information on hypoglycaemia
- to assess changes in glucose control resulting from medications and lifestyle changes
- to monitor changes during intercurrent illness
- to ensure safety during activities, including driving.

1.4.3 Assess at least annually and in a structured way:
- self-monitoring skills
- the quality and appropriate frequency of testing
- the use made of the results obtained
- the impact on quality of life
1.4.4 If self-monitoring is appropriate but blood glucose monitoring is unacceptable to the individual, discuss the use of urine glucose monitoring.

1.5 **Oral glucose control therapies (1): metformin, insulin secretagogues and acarbose**

1.5.1 Metformin

1.5.1.1 Start metformin treatment in a person who is overweight or obese (tailoring the assessment of body-weight-associated risk according to ethnic group\(^5\)) and whose blood glucose is inadequately controlled (see 1.3.1) by lifestyle interventions (nutrition and exercise) alone.

1.5.1.2 Consider metformin as an option for first-line glucose-lowering therapy for a person who is not overweight.

1.5.1.3 Continue with metformin if blood glucose control remains or becomes inadequate (see 1.3.1) and another oral glucose-lowering medication (usually a sulfonylurea) is added.

1.5.1.4 Step up metformin therapy gradually over weeks to minimise risk of gastro-intestinal (GI) side effects. Consider a trial of extended-absorption metformin tablets where GI tolerability prevents continuation of metformin therapy.

1.5.1.5 Review the dose of metformin if the serum creatinine exceeds 130 micromol/litre or the estimated glomerular filtration rate (eGFR) is below 45 ml/minute/1.73-m\(^2\).

- Stop the metformin if the serum creatinine exceeds 150 micromol/litre or the eGFR is below 30 ml/minute/1.73-m\(^2\).

• Prescribe metformin with caution for those at risk of a sudden
deterioration in kidney function and those at risk of eGFR falling
below 45 ml/minute/1.73-m$^2$.

1.5.1.6 The benefits of metformin therapy should be discussed with a
person with mild to moderate liver dysfunction or cardiac
impairment so that:
• due consideration can be given to the cardiovascular-protective
effects of the drug
• an informed decision can be made on whether to continue or
stop the metformin.

1.5.2 Insulin secretagogues

1.5.2.1 Consider a sulfonylurea as an option for first-line glucose-lowering
therapy if:
• the person is not overweight
• the person does not tolerate metformin (or it is contraindicated)
or
• a rapid response to therapy is required because of
hyperglycaemic symptoms.

1.5.2.2 Add a sulfonylurea as second-line therapy when blood glucose
control remains or becomes inadequate (see 1.3.1) with metformin.

1.5.2.3 Continue with a sulfonylurea if blood glucose control remains or
becomes inadequate (see 1.3.1) and another oral glucose-lowering
medication is added.

1.5.2.4 Prescribe a sulfonylurea with a low acquisition cost (but not
glibenclamide) when an insulin secretagogue is indicated (see
1.5.2.1 and 1.5.2.2).

1.5.2.5 When drug concordance is a problem, offer a once-daily, long-
acting sulfonylurea.
1.5.2.6 Educate a person being treated with an insulin secretagogue, particularly if renally impaired, about the risk of hypoglycaemia.

1.5.3 Rapid-acting insulin secretagogues
1.5.3.1 Consider offering a rapid-acting insulin secretagogue to a person with an erratic lifestyle.

1.5.4 Acarbose
1.5.4.1 Consider acarbose for a person unable to use other oral glucose-lowering medications.

1.6 Oral glucose control therapies (2): other oral agents and exenatide

This section, covering glitazones, gliptins and exenatide, will be updated in the NICE short clinical guideline ‘Newer agents for blood glucose in type 2 diabetes’ (publication expected in February 2009).

1.6.1 Thiazolidinediones (glitazones)\(^6\)
1.6.1.1 If glucose concentrations are not adequately controlled (to \(\text{HbA}_1\text{c} < 7.5\%\) or other higher level agreed with the individual), consider, after discussion with the person, adding a thiazolidinedione to:
- the combination of metformin and a sulfonylurea if human insulin is likely to be unacceptable or ineffective because of employment, social or recreational issues related to putative hypoglycaemia, injection anxieties, other personal issues, or obesity/metabolic syndrome
- a sulfonylurea if metformin is not tolerated
- metformin as an alternative to a sulfonylurea where the person’s job or other issues make the risk of hypoglycaemia with sulfonylureas particularly significant.

\(^6\) The recommendations in this section replace ‘Guidance on the use of glitazones for the treatment of type 2 diabetes’ (NICE technology appraisal guidance 63).
1.6.1.2 Warn a person prescribed a thiazolidinedione about the possibility of significant oedema and advise on the action to take if it develops.

1.6.1.3 Do not commence or continue a thiazolidinedione in people who have evidence of heart failure, or who are at higher risk of fracture.

1.6.1.4 When selecting a thiazolidinedione for initiation and continuation of therapy, take into account up-to-date advice from the relevant regulatory bodies (the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency), cost and safety issues (note that only pioglitazone can be used in combination with insulin therapy, see recommendation 1.7.1.3).

1.6.2 Gliptins – GLP-1 enhancers

No recommendations are made on the use of gliptins as these drugs are not covered in this guideline.

1.6.3 Exenatide – GLP-1 mimetic

1.6.3.1 Exenatide is not recommended for routine use in type 2 diabetes.

1.6.3.2 Consider exenatide as an option only if all the following apply for the individual:
- a body mass index over 35.0 kg/m\(^2\) in those of European descent, with appropriate adjustment in tailoring this advice for other ethnic groups
- specific problems of a psychological, biochemical or physical nature arising from high body weight
- inadequate blood glucose control (HbA\(_{1c}\) ≥ 7.5%) with conventional oral agents after a trial of metformin and sulfonylurea
- other high-cost medication, such as a thiazolidinedione or insulin injection therapy, would otherwise be started.
1.6.3.3 
Continue exenatide therapy only if a beneficial metabolic response (at least 1.0 percentage point HbA1c reduction in 6 months and a weight loss of at least 5% at 1 year) occurs and is maintained.

1.7 
**Glucose control: insulin therapy**

1.7.1 
**Oral agent combination therapy with insulin**

1.7.1.1 
When starting basal insulin therapy:
- continue with metformin and the sulfonylurea (and acarbose, if used)
- review the use of the sulfonylurea if hypoglycaemia occurs.

1.7.1.2 
When starting pre-mixed insulin therapy (or mealtime plus basal insulin regimens):
- continue with metformin
- continue the sulfonylurea initially, but review and discontinue if hypoglycaemia occurs.

1.7.1.3 
Consider combining pioglitazone with insulin therapy for:
- a person who has previously had a marked glucose-lowering response to thiazolidinedione therapy
- a person on high-dose insulin therapy whose blood glucose is inadequately controlled.

Warn the person to discontinue pioglitazone if clinically significant fluid retention develops.

1.7.2 
**Insulin therapy**

1.7.2.1 
When other measures no longer achieve adequate blood glucose control (to HbA1c < 7.5% or other higher level agreed with the individual), discuss the benefits and risks of insulin therapy. Start insulin therapy if the person agrees.

1.7.2.2 
When starting insulin therapy, use a structured programme employing active insulin dose titration that encompasses:
- structured education
• continuing telephone support
• frequent self-monitoring
• dose titration to target
• dietary understanding
• management of hypoglycaemia
• management of acute changes in plasma glucose control
• support from an appropriately trained and experienced healthcare professional.

1.7.2.3 Insulin therapy should be initiated from a choice of a number of insulin types and regimens.
• Preferably begin with human NPH insulin, taken at bed-time or twice daily according to need.
• Consider, as an alternative, using a long-acting insulin analogue (insulin glargine) for a person who falls into one of the following categories:\(^7\):
  − Those who require assistance from a carer or healthcare professional to administer their insulin injections.
  − Those whose lifestyle is significantly restricted by recurrent symptomatic hypoglycaemic episodes.
  − Those who would otherwise need twice-daily basal insulin injections in combination with oral glucose-lowering medications.
• Consider twice-daily biphasic human insulin (pre-mix) regimens in particular where HbA\(_{1c}\) is elevated above 9.0%. A once-daily regimen may be an option when initiating this therapy.
• Consider pre-mixed preparations of insulin analogues rather than pre-mixed human insulin preparations when:
  − immediate injection before a meal is preferred, or
  − hypoglycaemia is a problem, or
  − there are marked postprandial blood glucose excursions.

---

\(^7\) This recommendation replaces the recommendations on type 2 diabetes in ‘Guidance on the use of long-acting insulin analogues for the treatment of diabetes – insulin glargine’ (NICE technology appraisal guidance 53).
1.7.2.4 Offer a trial of insulin glargine if a person who has started with NPH insulin experiences significant nocturnal hypoglycaemia.

1.7.2.5 Monitor a person using a basal insulin regimen (NPH or a long-acting insulin analogue [insulin glargine]) for the need for mealtime insulin (or a pre-mixed insulin preparation). If blood glucose control remains inadequate (not to agreed target levels without problematic hypoglycaemia), move to a more intensive, mealtime plus basal insulin regimen based on the option of human or analogue insulins.

1.7.2.6 Monitor a person using pre-mixed insulin once or twice daily for the need for a further preprandial injection or for an eventual change to a mealtime plus basal insulin regimen, based on human or analogue insulins, if blood glucose control remains inadequate.

1.7.3 **Insulin detemir**

Insulin detemir is not covered by this guideline.\(^8\)

1.7.4 **Insulin delivery devices**

1.7.4.1 Offer education to a person who requires insulin about using an injection device (usually a pen injector and cartridge or a disposable pen) that they and/or their carer find easy to use.

1.7.4.2 Appropriate local arrangements should be in place for the disposal of sharps.

1.7.4.3 If a person has a manual or visual disability and requires insulin, offer a device or adaptation that:

- takes into account his or her individual needs
- he or she can use successfully.

---

\(^8\) Insulin detemir will be covered by the NICE short clinical guideline ‘Newer agents for blood glucose control in type 2 diabetes’ (publication expected in February 2009).
1.8 **Blood pressure therapy**

1.8.1 Measure blood pressure at least annually in a person without previously diagnosed hypertension or renal disease. Offer and reinforce preventive lifestyle advice.

1.8.2 For a person on antihypertensive therapy at diagnosis of diabetes, review control of blood pressure and medications used, and make changes only where there is poor control or where current medications are not appropriate because of microvascular complications or metabolic problems.

1.8.3 Repeat blood pressure (BP) measurements within:
- 1 month if BP is higher than 150/90 mmHg
- 2 months if BP is higher than 140/80 mmHg
- 2 months if BP is higher than 130/80 mmHg and there is kidney, eye or cerebrovascular damage.

Offer lifestyle advice (diet and exercise) at the same time.

1.8.4 Offer lifestyle advice (see dietary recommendations in section 1.2.1 of this guideline and the lifestyle recommendations in section 1.2 of ‘Hypertension: management of hypertension in adults in primary care’ [NICE clinical guideline 34]) if blood pressure is confirmed as being consistently above 140/80 mmHg (or above 130/80 mmHg if there is kidney, eye or cerebrovascular damage).

1.8.5 Add medications if lifestyle advice does not reduce blood pressure to below 140/80 mmHg (below 130/80 mmHg if there is kidney, eye or cerebrovascular damage).

1.8.6 Monitor blood pressure 1–2-monthly, and intensify therapy if on medications until blood pressure is consistently below 140/80 mmHg (below 130/80 mmHg if there is kidney, eye or cerebrovascular disease).

1.8.7 First-line blood-pressure-lowering therapy should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor. Exceptions
to this are people of African-Caribbean descent or women for whom there is a possibility of becoming pregnant (see 1.8.8 and 1.8.9).

1.8.8 First-line blood-pressure-lowering therapy for a person of African-Caribbean descent should be an ACE inhibitor plus either a diuretic or a generic calcium-channel antagonist (calcium-channel blocker).

1.8.9 A calcium-channel blocker should be the first-line blood-pressure-lowering therapy for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.

1.8.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.

1.8.11 If the person’s blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually bendroflumethiazide, 2.5 mg daily). Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy.

1.8.12 If the person’s blood pressure is not reduced to the individually agreed target with triple therapy (see 1.8.11), add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the individual is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).

1.8.13 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months, and check for possible adverse effects of antihypertensive therapy – including the risks from unnecessarily low blood pressure.
1.9 **Cardiovascular risk estimation**

1.9.1 Consider a person to be at high premature cardiovascular risk for his or her age unless he or she:
- is not overweight, tailoring this with an assessment of body-weight-associated risk according to ethnic group\(^9\)
- is normotensive (< 140/80 mmHg in the absence of antihypertensive therapy)
- does not have macroalbuminuria
- does not smoke
- does not have a high-risk lipid profile
- has no history of cardiovascular disease and
- has no family history of cardiovascular disease.

1.9.2 If the person is considered not to be at high cardiovascular risk, estimate cardiovascular risk annually using the UK Prospective Diabetes Study (UKPDS) risk engine (see www.dtu.ox.ac.uk/index.php?maindoc=/riskengine/).

1.9.3 Consider using cardiovascular risk estimates from the UKPDS risk engine (see 1.9.2) for educational purposes when discussing cardiovascular complications with the individual.

1.9.4 Perform a full lipid profile (including high-density lipoprotein [HDL] cholesterol and triglyceride estimations) when assessing cardiovascular risk after diagnosis and annually, and before starting lipid-modifying therapy.

1.10 **Management of blood lipid levels**

1.10.1 **Statins and ezetimibe**

1.10.1.1 Review cardiovascular risk status annually by assessment of cardiovascular risk factors, including features of the metabolic

---

\(^9\) See ‘Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children (NICE clinical guideline 43). (www.nice.org.uk/CG043)
syndrome and waist circumference, and change in personal or family cardiovascular history.

1.10.1.2 For a person who is 40 years old or over:
- initiate therapy with generic simvastatin (to 40 mg) or a statin of similar efficacy and cost unless the cardiovascular risk from non-hyperglycaemia-related factors is low (see 1.9.1)
- if the cardiovascular risk from non-hyperglycaemia-related factors is low, assess cardiovascular risk using the UKPDS risk engine (see 1.9.2) and initiate simvastatin therapy (to 40 mg), or a statin of similar efficacy and cost, if the cardiovascular risk exceeds 20% over 10 years.

1.10.1.3 For a person who is under 40 years old, consider initiating generic simvastatin therapy (to 40 mg), or a statin of similar efficacy and cost, where the cardiovascular risk factor profile appears particularly poor (multiple features of the metabolic syndrome, presence of conventional risk factors, microalbuminuria, at-risk ethnic group, or strong family history of premature cardiovascular disease).

1.10.1.4 Once a person has been started on cholesterol-lowering therapy, assess his or her lipid profile (together with other modifiable risk factors and any new diagnosis of cardiovascular disease) 1–3 months after starting treatment, and annually thereafter. In those not on cholesterol-lowering therapy, reassess cardiovascular risk annually and consider initiating a statin (see 1.10.1.2 and 1.10.1.3).

1.10.1.5 Increase the dose of simvastatin, in anyone initiated on simvastatin in line with the above recommendations, to 80 mg daily unless total cholesterol level is below 4.0 mmol/litre or low-density lipoprotein [LDL] cholesterol level is below 2.0 mmol/litre.
1.10.1.6 Consider intensifying cholesterol-lowering therapy (with a more effective statin or ezetimibe in line with NICE guidance)\textsuperscript{10} if there is existing or newly diagnosed cardiovascular disease, or if there is an increased albumin excretion rate, to achieve a total cholesterol level below 4.0 mmol/litre (and HDL cholesterol not exceeding 1.4 mmol/litre) or an LDL cholesterol level below 2.0 mmol/litre.

1.10.1.7 If there is a possibility of a woman becoming pregnant, do not use statins unless the issues have been discussed with the woman and agreement has been reached.

1.10.2 Fibrates

1.10.2.1 If there is a history of elevated serum triglycerides, perform a full fasting lipid profile (including HDL cholesterol and triglyceride estimations) when assessing cardiovascular risk annually.

1.10.2.2 Assess possible secondary causes of high serum triglyceride levels, including poor blood glucose control (others include hypothyroidism, renal impairment and liver inflammation, particularly from alcohol). If a secondary cause is identified, manage according to need.

1.10.2.3 Prescribe a fibrate (fenofibrate as first-line) if triglyceride levels remain above 4.5 mmol/litre despite attention to other causes. In some circumstances, this will be before a statin has been started because of acute need (that is, risk of pancreatitis) and because of the undesirability of initiating two drugs at the same time.

1.10.2.4 If cardiovascular risk is high (as is usual in people with type 2 diabetes), consider adding a fibrate to statin therapy if triglyceride levels remain in the range 2.3–4.5 mmol/litre despite statin therapy.

\textsuperscript{10} ‘Statins for the prevention of cardiovascular events’ (NICE technology appraisal guidance 94); ‘Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia’ (NICE technology appraisal guidance 132).
1.10.3 Nicotinic acid

1.10.3.1 Do not use nicotinic acid preparations and derivatives routinely for people with type 2 diabetes. They may have a role in a few people who are intolerant of other therapies and have more extreme disorders of blood lipid metabolism, when managed by those with specialist expertise in this area.

1.10.4 Omega-3 fish oils

1.10.4.1 Do not prescribe fish oil preparations for the primary prevention of cardiovascular disease in people with type 2 diabetes. This recommendation does not apply to people with hypertriglyceridaemia receiving advice from a healthcare professional with special expertise in blood lipid management.

1.10.4.2 Consider a trial of highly concentrated, licensed omega-3 fish oils for refractory hypertriglyceridaemia if lifestyle measures and fibrate therapy have failed.

1.11 Anti-thrombotic therapy

1.11.1 Offer low-dose aspirin, 75 mg daily, to a person who is 50 years old or over, if blood pressure is below 145/90 mmHg.

1.11.2 Offer low-dose aspirin, 75 mg daily, to a person who is under 50 years old and has significant other cardiovascular risk factors (features of the metabolic syndrome, strong early family history of cardiovascular disease, smoking, hypertension, extant cardiovascular disease, microalbuminuria).

1.11.3 Clopidogrel should be used instead of aspirin only in those with clear aspirin intolerance (except in the context of acute cardiovascular events and procedures). Follow the recommendations in ‘Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events’ (NICE technology appraisal guidance 90).
1.12 **Kidney damage**

1.12.1 Ask all people with or without detected nephropathy to bring in a first-pass morning urine specimen once a year. In the absence of proteinuria/urinary tract infection (UTI), send this for laboratory estimation of albumin:creatinine ratio. Request a specimen on a subsequent visit if UTI prevents analysis.

1.12.2 Make the measurement on a spot sample if a first-pass sample is not provided (and repeat on a first-pass specimen if abnormal) or make a formal arrangement for a first-pass specimen to be provided.

1.12.3 Measure serum creatinine and estimate the glomerular filtration rate (using the method-abbreviated modification of diet in renal disease [MDRD] four-variable equation) annually at the time of albumin:creatinine ratio estimation.

1.12.4 Repeat the test if an abnormal albumin:creatinine ratio is obtained (in the absence of proteinuria/UTI) at each of the next two clinic visits but within a maximum of 3–4 months. Take the result to be confirming microalbuminuria if a further specimen (out of two more) is also abnormal (> 2.5 mg/mmol for men, > 3.5 mg/mmol for women).

1.12.5 Suspect renal disease other than diabetic nephropathy and consider further investigation or referral when the albumin:creatinine ratio (ACR) is raised and any of the following apply:

- there is no significant or progressive retinopathy
- blood pressure is particularly high or resistant to treatment
- the person previously had a documented normal ACR and develops heavy proteinuria (ACR > 100 mg/mmol)
- significant haematuria is present
- the glomerular filtration rate has worsened rapidly
• the person is systemically ill.

1.12.6 Discuss the significance of a finding of abnormal albumin excretion rate, and its trend over time, with the individual concerned.

1.12.7 Start ACE inhibitors with the usual precautions and titrate to full dose in all individuals with confirmed raised albumin excretion rate (> 2.5 mg/mmol for men, > 3.5 mg/mmol for women).

1.12.8 Have an informed discussion before starting an ACE inhibitor in a woman for whom there is a possibility of pregnancy, assessing the relative risks and benefits of the use of the ACE inhibitor.

1.12.9 Substitute an angiotensin II-receptor antagonist for an ACE inhibitor for a person with an abnormal albumin:creatinine ratio if an ACE inhibitor is poorly tolerated.

1.12.10 For a person with an abnormal albumin:creatinine ratio, maintain blood pressure below 130/80 mmHg.

1.12.11 Agree referral criteria for specialist renal care between local diabetes specialists and nephrologists.

1.13 **Eye damage**

1.13.1 Arrange or perform eye screening at or around the time of diagnosis. Arrange repeat of structured eye surveillance annually.

1.13.2 Explain the reasons for, and success of, eye surveillance systems to the individual and ensure attendance is not reduced by ignorance of need or fear of outcome.

1.13.3 Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages. Discussions should include precautions for driving.
1.13.4 Use a quality-assured digital retinal photography programme using appropriately trained staff.

1.13.5 Perform visual acuity testing as a routine part of eye surveillance programmes.

1.13.6 Repeat structured eye surveillance according to the findings by:
   • routine review in 1 year, or
   • earlier review, or
   • referral to an ophthalmologist.

1.13.7 Arrange emergency review by an ophthalmologist for:
   • sudden loss of vision
   • rubeosis iridis
   • pre-retinal or vitreous haemorrhage
   • retinal detachment.

1.13.8 Arrange rapid review by an ophthalmologist for new vessel formation.

1.13.9 Refer to an ophthalmologist in accordance with the National Screening Committee criteria and timelines if any of these features is present:
   • referable maculopathy:
     – exudate or retinal thickening within one disc diameter of the centre of the fovea
     – circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea)
     – any microaneurysm or haemorrhage within one disc diameter of the centre of the fovea, only if associated with deterioration of best visual activity to 6/12 or worse.
• referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy):
  – any venous beading
  – any venous loop or reduplication
  – any intraretinal microvascular abnormalities
  – multiple deep, round or blot haemorrhages
• any unexplained drop in visual acuity.

1.14  **Nerve damage**

1.14.1 For the management of foot problems relating to type 2 diabetes, follow recommendations in ‘Type 2 diabetes: prevention and management of foot problems’ (NICE clinical guideline 10).

1.14.2  **Diabetic neuropathic pain management**

1.14.2.1 Make a formal enquiry annually about the development of neuropathic symptoms causing distress.
• Discuss the cause and prognosis (including possible medium-term remission) of troublesome neuropathic symptoms, if present (bearing in mind alternative diagnoses).
• Agree appropriate therapeutic options and review understanding at each clinical contact.

1.14.2.2 Be alert to the psychological consequences of chronic, painful diabetic neuropathy and offer psychological support according to the needs of the individual.

1.14.2.3 Use a tricyclic drug to treat neuropathic discomfort (start with low doses, titrated as tolerated) if standard analgesic measures have not worked, timing the medication to be taken before the time of day when the symptoms are troublesome; advise that this is a trial of therapy.

1.14.2.4 Offer a trial of duloxetine, gabapentin or pregabalin if a trial of tricyclic drug does not provide effective pain relief. The choice of

NICE clinical guideline 66 – type 2 diabetes  29
drug should be determined by current drug prices. Trials of these therapies should be stopped if the maximally tolerated drug dose is ineffective. If side effects limit effective dose titration, try another one of the drugs.

1.14.2.5 Consider a trial of opiate analgesia if severe chronic pain persists despite trials of other measures. If there is inadequate relief of the pain associated with diabetic neuropathic symptoms, seek the assistance of a chronic pain management service following a discussion with the person concerned.

1.14.2.6 If drug management of diabetic neuropathic pain has been successful, consider reducing the dose and stopping therapy following discussion and agreement with the individual.

1.14.2.7 If neuropathic symptoms cannot be controlled adequately, it may be helpful to further discuss:
- the reasons for the problem
- the likelihood of remission in the medium term
- the role of improved blood glucose control.

1.14.3 **Gastroparesis**

1.14.3.1 Consider the diagnosis of gastroparesis in an adult with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into consideration possible alternative diagnoses.

1.14.3.2 Consider a trial of metoclopramide, domperidone or erythromycin for an adult with gastroparesis.

1.14.3.3 If gastroparesis is suspected, consider referral to specialist services if:
- the differential diagnosis is in doubt, or
- persistent or severe vomiting occurs.

1.14.4 **Erectile dysfunction**

1.14.4.1 Review the issue of erectile dysfunction with men annually.
1.14.4.2 Provide assessment and education for men with erectile dysfunction to address contributory factors and treatment options.

1.14.4.3 Offer a phosphodiesterase-5 inhibitor (choosing the drug with the lowest acquisition cost), in the absence of contraindications, if erectile dysfunction is a problem.

1.14.4.4 Following discussion, refer to a service offering other medical, surgical, or psychological management of erectile dysfunction if phosphodiesterase-5 inhibitors have been unsuccessful.

1.14.5 Other aspects of autonomic neuropathy

1.14.5.1 Consider the possibility of contributory sympathetic nervous system damage for a person who loses the warning signs of hypoglycaemia.

1.14.5.2 Consider the possibility of autonomic neuropathy affecting the gut in an adult with unexplained diarrhoea, particularly at night.

1.14.5.3 When using tricyclic drugs and antihypertensive medications in people with autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.

1.14.5.4 Investigate a person with unexplained bladder-emptying problems for the possibility of autonomic neuropathy affecting the bladder.

1.14.5.5 Include in the management of autonomic neuropathy symptoms the specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).

2 Notes on the scope of the guidance

NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover. The scope of this guideline is available from www.nice.org.uk/CG066
The application of the guideline to children has not been excluded. However, we were not able to specifically search for paediatric literature due to the volume of work involved. Healthcare professionals need to use their clinical judgement when applying this guideline to children. For further assistance with applying this guideline to children, refer to the ‘British national formulary for children’ (BNFC) 2007.

**How this guideline was developed**

NICE commissioned the National Collaborating Centre for Chronic Conditions to develop this guideline. The Centre established a Guideline Development Group (see appendix A), which reviewed the evidence and developed the recommendations. An independent Guideline Review Panel oversaw the development of the guideline (see appendix B).

There is more information in the booklet: ‘The guideline development process: an overview for stakeholders, the public and the NHS’ (third edition, published April 2007), which is available from www.nice.org.uk/guidelinesprocess or from NICE publications (phone 0845 003 7783 or email publications@nice.org.uk and quote reference N1233).

**3 Implementation**

The Healthcare Commission assesses the performance of NHS organisations in meeting core and developmental standards set by the Department of Health in ‘Standards for better health’ (available from www.dh.gov.uk). Implementation of clinical guidelines forms part of the developmental standard D2. Core standard C5 says that national agreed guidance should be taken into account when NHS organisations are planning and delivering care.
NICE has developed tools to help organisations implement this guidance (listed below). These are available on our website (www.nice.org.uk/CG066).

- Slides highlighting key messages for local discussion.
- Costing statement to help estimate the costs and savings involved in implementing this guideline.
- Audit criteria to monitor local practice.

4 Research recommendations

The Guideline Development Group has made the following recommendations for research, based on its review of evidence, to improve NICE guidance and patient care in the future.

4.1 Glucose control: oral glucose-lowering therapy

Metformin: confirmatory studies of the advantage in terms of cardiovascular outcome studies.

Why this is important
The UKPDS study confirmed that metformin offered cardiovascular protection. However, the extent of the relative risk reduction was unexpectedly large and needs formal testing in a further study. This is critical to the positioning of metformin in the treatment cascade.

4.2 Glucose control: oral glucose-lowering therapy

Studies of the role of sulfonylureas when starting a pre-mixed insulin preparation.

Why this is important
Both pre-mixed insulins and sulfonylureas are effective glucose-lowering agents throughout the day, but can cause hypoglycaemia. When starting insulin, continuing sulfonylureas prevents deterioration of glucose control during insulin dose titration and reduces the requirement for insulin. However, it is not clear that these advantages are not offset by an increased risk of hypoglycaemia.
4.3 Self-monitoring of plasma glucose

Longer-term studies of the role of self-monitoring as part of an integrated package with patient education and therapies used to target.

**Why this is important**

Studies of self-monitoring, in people not using insulin, continue to fail to address the complicated issue of its integration into patient education and self-management behaviours. Self-monitoring can be moderately expensive and a significant burden if not used appropriately. While it is accepted that study designs are difficult in this area, the positive results from large observational studies need further support.

4.4 Blood-pressure-lowering medications

The use of ACE inhibitors and angiotensin II-receptor antagonists in combination in early diabetic nephropathy.

**Why this is important**

Both of these classes of renin–angiotensin system blockers are effective in reducing the rate of progression of diabetic kidney damage. However, there are acute risks of side effects associated with both classes of drug. As these risks are similar, it is not clear whether the expected combined benefit from ACE inhibitors and angiotensin II-receptor antagonists would outweigh the combined risks.

4.5 Diabetic neuropathic pain management

Comparison studies on tricyclic drugs, duloxetine, gabapentin and pregabalin.

**Why this is important**

While all these drugs are partially effective in the control of neuropathic pain, they differ in cost and side-effect profile. This makes the recommendations of treatment cascade uncertain to some extent. There is a need for comparative studies between these drugs and, in particular, of the newer agents with the tricyclic drugs.
5 Other versions of this guideline

5.1 Full guideline
The full guideline, ‘Type 2 diabetes (update): national clinical guideline for management in primary and secondary care’ contains details of the methods and evidence used to develop the guideline. It is published by the National Collaborating Centre for Chronic Conditions and is available from www.rcplondon.ac.uk/pubs/brochure.aspx?e=247, our website (www.nice.org.uk/CG066fullguideline) and the National Library for Health (www.nlh.nhs.uk).

5.2 Quick reference guide
A quick reference guide for healthcare professionals is available from www.nice.org.uk/CG066quickrefguide

For printed copies, phone NICE publications on 0845 003 7783 or email publications@nice.org.uk (quote reference number N1572).

5.3 ‘Understanding NICE guidance’
Information for patients and carers (‘Understanding NICE guidance’) is available from www.nice.org.uk/CG066publicinfo

For printed copies, phone NICE publications on 0845 003 7783 or email publications@nice.org.uk (quote reference number N1573).

6 Related NICE guidance

Published

Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. NICE public health guidance 10 (2008). Available from www.nice.org.uk/PH010

Promoting and creating built or natural environments that encourage and support physical activity. NICE public health guidance 8 (2008). Available from www.nice.org.uk/PH008


Four commonly used methods to increase physical activity: brief interventions in primary care, exercise referral schemes, pedometers and community-based exercise programmes for walking and cycling. NICE public health intervention guidance 2 (2006). Available from www.nice.org.uk/PHI002


NICE clinical guideline 66 – type 2 diabetes


Under development

NICE is developing the following guidance (details available from www.nice.org.uk):


- Newer agents for blood glucose control in type 2 diabetes. NICE clinical guideline (publication expected February 2009).

7 Updating the guideline

NICE clinical guidelines are updated as needed so that recommendations take into account important new information. We check for new evidence 2 and 4 years after publication, to decide whether all or part of the guideline should be updated. If important new evidence is published at other times, we may decide to do a more rapid update of some recommendations.
Appendix A: The Guideline Development Group

Mrs Lina Bakhshi
Information Scientist, NCC-CC

Ms Margaret Bannister
Nurse Consultant in Diabetes Care

Mrs Katherine Cullen
Health Economist, NCC-CC, and Research Fellow, Queen Mary University of London

Professor Melanie Davies
Professor of Diabetes Medicine, University of Leicester

Dr Jose Diaz
Health Services Research Fellow in Guideline Development, NCC-CC

Mrs Barbara Elster
Patient and Carer Representative, Essex

Dr Roger Gadsby
General Practitioner and Senior Lecturer in Primary Care, Warwickshire

Dr Anupam Garrib
Health Services Research Fellow in Guideline Development, NCC-CC

Ms Irene Gummerson
Primary Care Pharmacist, Yorkshire

Dr Martin Hadley-Brown
General Practitioner (trainer), University of Cambridge

Professor Philip Home (Clinical Adviser to the GDG)
Professor of Diabetes Medicine, Newcastle University

Mrs Kathryn Leivesley
Practice Nurse, North Manchester PCT

NICE clinical guideline 66 – type 2 diabetes
Professor Jonathan Mant (Chair)
Professor of Primary Care Stroke Research, University of Birmingham

Mrs Emma Marcus
Clinical Specialist Diabetes Dietitian, Hinckley and Bosworth PCT

Mr Leo Nherera
Health Economist, National Collaborating Centre for Women’s and Children’s Health

Ms Roberta Richey
Health Services Research Fellow in Guideline Development, NCC-CC

Mr John Roberts
Patient and Carer Representative, Merseyside

Dr Mark Savage
Consultant Physician, North Manchester General Hospital

Dr Stuart Smellie
Consultant Chemical Pathologist, Bishop Auckland General Hospital

Ms Nicole Stack
Guideline Development Project Manager, NCC-CC

Ms Claire Turner
Guideline Development Project Manager, NCC-CC

Ms Susan Varney
Health Services Research Fellow in Guideline Development, NCC-CC

Dr Jiten Vora
Consultant Physician Endocrinologist, Royal Liverpool and Broadgreen University Hospitals

NICE clinical guideline 66 – type 2 diabetes
The following experts were invited to attend specific meetings and to advise the Guideline Development Group:

Dr Julian Barth
Consultant Chemical Pathologist, Leeds NHS Trust (attended one meeting as a deputy for Dr Stuart Smellie)

Dr Indranil Dasgupta
Consultant Physician and Nephrologist, Birmingham Heartlands Hospital

Dr Michael Feher
Consultant Physician, Chelsea Westminster Hospital (attended one meeting as a deputy for Dr Mark Savage)

Dr Charles Fox
Consultant Physician, Northampton General Trust (attended one meeting as a deputy for Professor Melanie Davies)

Natasha Jacques
Principal Pharmacist, Solihull Hospital (attended one meeting as a deputy for Ms Irene Gummerson)

Dr Eric Kilpatrick
Consultant Chemical Pathologist, University of Hull (attended one meeting as a deputy for Dr Stuart Smellie)

Dr Ian Lawrence
Consultant Diabetologist, University of Leicester (attended one meeting as a deputy for Professor Melanie Davies and Dr Jiten Vora)

Professor Sally Marshall
Professor of Diabetes, Newcastle University

Professor David Wood
Professor of Cardiovascular Medicine, Imperial College London
Appendix B: The Guideline Review Panel

The Guideline Review Panel is an independent panel that oversees the development of the guideline and takes responsibility for monitoring adherence to NICE guideline development processes. In particular, the panel ensures that stakeholder comments have been adequately considered and responded to. The panel includes members from the following perspectives: primary care, lay, public health and industry.

**Dr Robert Walker (Chair)**
General Practitioner, Cumbria

**Dr Mark Hill**
Head of Medical Affairs, Novartis Pharmaceuticals UK

**Dr John Harley**
Clinical Governance and Prescribing Lead, North Tees PCT

**Ailsa Donnelly**
Lay member
Appendix C: The algorithms

**HbA\(_1c\) ≥ 6.5%** after trial of lifestyle measures

- **metformin** with active dose titration
  - **HbA\(_1c\) < 6.5%**
    - **HbA\(_1c\) ≥ 6.5%**
      - **monitor for expected deterioration**
        - **metformin + sulphonylurea** with active dose titration
          - **monitor for expected deterioration**
            - **HbA\(_1c\) ≥ 7.5%**
              - add **thiazolidinedione** or **insulin** with active dose titration
                - **HbA\(_1c\) ≥ 7.5%**
                  - **insulin + metformin + sulphonylurea** with active dose titration
                    - **monitor for expected deterioration**
                      - increase insulin dose and intensify regimen with time

- **A sulphonylurea** may be considered here for people who are not overweight or if glucose levels are particularly high

- **A rapid acting insulin secretagogue** may be considered for people with non-routine daily lifestyle patterns to assist in attaining glucose control to their individual target.
  - Only consider a thiazolidinedione here if hypoglycaemia on sulphonylurea is a potential problem.

- **Exenatide** may be considered here when body weight is a special problem and recommendations in the guideline are met.

Scheme for the pharmacotherapy of glucose-lowering in people with type 2 diabetes

For details see recommendations on glucose-lowering targets, clinical monitoring, use of oral agents, and use of insulin

NICE clinical guideline 66 – type 2 diabetes 42
Measure BP annually if not hypertensive or renal disease
If >140/80 mmHg confirm consistently raised

Targets
People with retinopathy or cerebrovascular disease
or with microalbuminuria
Follow algorithm with target <130/80 mmHg

Others
Follow algorithm with target <140/80 mmHg

Trial lifestyle measures alone unless >150/90 mmHg

Women with possibility of pregnancy
Avoid use of ACEI or A2RB drugs
Begin with CCB
In people with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia)
substitute the ACE inhibitor with an A2RB drug.

Maintain lifestyle measures

Start ACEI (and titrate dose)
(if African-Caribbean plus diuretic or plus CCB)

People with microalbuminuria
Will already be on full dose ACEI or alternative
Then follow algorithm with target <130/80 mmHg

Add CCB or bendroflumethiazide

above target

Add bendroflumethiazide or CCB

above target

Add α-blocker, β-blocker, or potassium-sparing diuretic

above target

Add α-blocker, β-blocker, or potassium-sparing diuretic, or refer to specialist

above target

Scheme for the management of blood pressure for people with type 2 diabetes

ACEI, ACE inhibitor;
A2RB, angiotensin 2 receptor blocker (sartan);
CCB, calcium channel blocker
**Diabetic symptomatic neuropathy management - a therapeutic summary**

<table>
<thead>
<tr>
<th>Non-severe</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Offer local measures and simple analgesia</td>
<td>Offer local measures and trial of tricyclic medication; monitor for response</td>
</tr>
<tr>
<td>Monitor for worsening</td>
<td>Monitor for worsening or remission</td>
</tr>
</tbody>
</table>

- **Maintain good blood glucose control**

- **Assess severity if present**
  - (sleep disturbance, depression, interference with normal activities)
  - (paraesthesiae, burning sensations, shooting pains, other)

- **Enquire annually for neuropathic symptoms**
  - (paraesthesiae, burning sensations, shooting pains, other)

- **Monitor for worsening**
  - controlled
  - Monitor for worsening or remission

- **Add a trial of the cheapest (at maximum dose) of duloxetine, gabapentin, or pregabalin – monitor for response**
  - controlled
  - Monitor for worsening or remission

- **Consider a trial of another of duloxetine, gabapentin, or pregabalin – titrate dose and monitor for response**
  - controlled
  - Monitor for worsening or remission

- **Uncontrolled**

*where neuropathic symptoms cannot be adequately controlled it is useful, to help individuals cope, to explain the reasons for the problem, the likelihood of remission in the medium term, the role of improved blood glucose control.*

---

NICE clinical guideline 66 – type 2 diabetes 44